008: Big Pharma vs. Low-Cost Cures: Evidence Behind the Claims that Suppression Exists

In this episode, we call B.S. on Big Pharma’s profit motives and explore how cheap or off-patent drugs often get sidelined – not by a grand conspiracy, but by a system that simply doesn’t reward low-margin cures. We discuss: Opioid Crisis Lawsuits: How Purdue Pharma and others downplayed risks and triggered a national epidemic. The Ivermectin Saga: Why a generic anti-parasitic got dismissed for COVID-19, stoking theories about suppressing cheap treatments. Cannabis & Psychedelics: Once deemed “no medical value,” now shown to help PTSD, depression, and more, but suppressed for decades. Real Influence on Research: Pharma funds trials, buries negative results, and fosters publication bias. Minor Mention of LDN: Low Dose Naltrexone as an example of an under-researched, generic therapy that might have big potential. Key Points & Discussion Opioid Crisis Lawsuits: Purdue Pharma’s role in pushing OxyContin, concealing addictive potential. Billions in settlements; internal memos showed profit-first tactics. Demonstrates Big Pharma’s willingness to prioritize sales over safety. WHO & Ivermectin Saga: Early COVID-19 hype vs. mainstream dismissal, fueling “suppression” talk. No major RCT funding from big sponsors – no profits to be made. Shows how “lack of data” can be a result of zero corporate interest. Cannabis & Psychedelics: They were Schedule I (“no medical value”) for decades, but new studies show clear benefits (pain, depression, etc.). Pharma’s disinterest in non-patentable compounds – overshadowed by new psych meds. Now a resurgence of research as big companies eye synthetic/novel forms for profit. Real Influence on Research: Evidence of publication bias; negative or unflattering results get hidden. Synthroid fiasco (study suppressed for 7 years), paying doctors, lobbying regulators. Reinforces that “profit over science” can hamper cheap, off-label therapies. LDN (Low Dose Naltrexone) Mention: Potential uses (fibromyalgia, Crohn’s), minimal side effects, but no big trials = less adoption. Symbolizes how unpatented therapies languish in R&D purgatory. References Opioid Crisis Lawsuits: US DOJ Opioid Settlement with Purdue Ivermectin & COVID-19: WHO Advice on Ivermectin Cannabis & Psychedelic Studies: Nature: Psilocybin for Depression RCT Influence on Research: BMJ: Publication bias in industry-funded trials LDN Trials Info: Penn State Crohn's LDN Study Listener Action Items Scrutinize Pharma Claims: Always ask who funds the trials, check for negative or missing data. Support Independent Research: Encourage public funding for generics & natural therapies so they're properly studied. Stay Skeptical: Don't dismiss everything mainstream, but remember profit motives shape the narrative. Connect & Subscribe If you enjoyed this episode, please leave a 5-star review on your favorite podcast platform! Questions or comments? Email [email protected] or DM us on IG: @icallbswithkb. Stay tuned for our next episode where we investigate more suspicious BS in the world of medicine, marketing, and beyond!